TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:CGEN) announced today that it has developed a GPCR ligand discovery engine and that use of the engine to date has resulted in Compugen’s discovery of eight novel peptides that activate GPCRs. The new peptide ligands will be presented at Screening Europe (February 20-21, 2007, Barcelona, Spain) and at CHI’s Molecular Medicine Tri-Conference (February 27-March 2, San Francisco, CA).
